A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of CCX354-C in Subjects With Rheumatoid Arthritis Partially Responsive to Methotrexate Therapy.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of CCX354-C in Subjects With Rheumatoid Arthritis Partially Responsive to Methotrexate Therapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Aug 2014

At a glance

  • Drugs CCX 354 (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms CARAT-2
  • Sponsors ChemoCentryx
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 09 Jun 2012 Results presented at the 13th Annual Congress of the European League Against Rheumatism.
    • 08 Jun 2012 Results were presented at the 13th Annual Congress of the European League Against Rheumatism (EULAR-2012), according to a ChemoCentryx media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top